Finder

External resources

• Luke Moore Imperial College London : https://www.imperial.ac.uk/people/l.moore
• Luke Moore Research Papers : https://orcid.org/0000-0001-7095-7922

Current NHS consultant posts held

Current posts:

Consultant Infectious Diseases, Microbiology, & Virology, Chelsea & Westminster NHS Foundation Trust
Consultant Medical Microbiology, North West London Pathology, Imperial College Healthcare NHS Trust
Honorary Clinical Senior Lecturer, Imperial College London

Research interests

Current research grants:

Chief Investigator (UK)/Principal Investigator (site): Retrospective Cefiderocol Study (PROVE).
Chief Investigator: SARS-CoV-2 in older people (SCALPEL).
Principal Investigator (site): Genetics of mortality in critical care (GenOMICC).
Principal Investigator: COVID-19 diagnostics evaluation and impact analysis.
Principal Investigator: Chelsea infectious diseases research (CINDER).
Co-Investigator: Randomised controlled trial of early favipiravir in COVID-19. (PIONEER).
Principal Investigator (site): Clinical Characterisation of Severe Emerging Infection (ISARIC).
Principal Investigator: Panton-Valentine Leukocidin S. aureus community transmission.
Principal Investigator (site): Observational Zavicefta Phase IV study (EZTEAM).
Principal Investigator (site): COVID19 community transmission (REACT 2).
Principal Investigator: Fomite microbial transmission in burns theatres.
Co-Investigator: Molecular diagnostics for ventilator-associated pneumonia (INHALE).

Publications

Selected Papers: I have published over 120 peer reviewed papers, with a h-Index of 26. In addition I have published 3 books, chapters in 7 further books, and presented over 100 abstracts at international conferences. Selected manuscripts in the last 2 years:

Pallett SJC, Denny SJ, Patel A, Charani E, Mughal N, Stebbing J, Davies G, Moore LSP. Point of care serological assays for SARS-CoV-2 in a UK hospital population: potential for enhanced case finding.Nat Scientific Reports.2021;11(1):5860.
Moshe M, Daunt A, Flower B, et al. SARS-CoV-2 Lateral Flow Assays for possible use in national COVID-19 seroprevalence surveys (REACT2): a diagnostic accuracy study.BMJ.2021;372:n423.
Rawson TM, Moore LSP, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing.Clin Infect Dis.2020;71(9):2459-2468.
Gibani MM, Toumazou C, Sohbati M, et al. Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study.Lancet Microbe.2020;1(7):300-307.
Pallett SJC, Rayment M, Patel A, Fitzgerald-Smith SAM, Denny SJ, Charani E, Mai AL, Gilmour KC, Hatcher J, Scott C, Randell P, Mughal N, Jones R, Davies GW†, Moore LSP†. Point-of-care serological assays for delayed SARS-CoV-2 case identification among UK healthcare workers; a prospective multicentre cohort study.Lancet Resp Med.2020;8(9):885-894.
Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalised patients with COVID-19: A retrospective cohort study in a UK secondary care setting.Clin Microbiol Infect.2020;26(10):1395-9.
Patel A, Charani E, Ariyanayagam D, Abdulaal A, Denny SJ, Mughal N, Moore LSP. New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection.Clin Microbiol Infect.2020;26(9):1236-41.
Rawson TM, Ming D, Ahmad R, Moore LSP, Holmes AH. Antimicrobial use, drug-resistant infections & COVID-19.Nat Rev Microbiol.2020;18(8):409-410.